Enalapril in the Management of Hypertension Associated With Renal Artery Stenosis

Vincent J. Canzonello, Michael P. Madaio, Nicolaos E. Madias

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Enalapril maleate (MK‐421) is a new non‐sulfhydryl‐containing converting‐enzyme inhibitor that has been shown to be effective and well tolerated in patients with essential hypertension. Data on its effectiveness and safety in patients with renovascular hypertension are limited and have involved predominantly short‐term observations. This is particularly true with respect to the long‐term effects of enalapril on renal function. We report our experience using the combination of enalapril and hydrochlorothiazide (HCTZ) in a group of nine patients with moderate to severe hypertension associated with renal artery stenosis. The enalapril‐HCTZ combination successfully controlled blood pressure in seven patients during a six‐week period of study. Adverse effects were not noted, and detailed renal hemodynamic studies did not reveal any significant changes of renal plasma flow and glomerular filtration rate during this time interval. Five patients were continued on this regimen for a period of six to 18 months. In this group of patients, the regimen continued to be well tolerated and to provide excellent blood pressure control: glomerular filtration rate was maintained in two patients and variable grades of decrease were noted in three. The mechanism of this delayed renal dysfunction as well as its relationship to enalapril treatment remain unclear. The long‐term impact of converting‐enzyme inhibition on renal function requires further study. 1987 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalThe Journal of Clinical Pharmacology
Volume27
Issue number1
DOIs
StatePublished - Jan 1 1987

Fingerprint

Renal Artery Obstruction
Enalapril
Hypertension
Kidney
Glomerular Filtration Rate
Blood Pressure
Renal Plasma Flow
Renovascular Hypertension
Hydrochlorothiazide
Clinical Pharmacology
Patient Safety
Hemodynamics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Enalapril in the Management of Hypertension Associated With Renal Artery Stenosis. / Canzonello, Vincent J.; Madaio, Michael P.; Madias, Nicolaos E.

In: The Journal of Clinical Pharmacology, Vol. 27, No. 1, 01.01.1987, p. 32-40.

Research output: Contribution to journalArticle

Canzonello, Vincent J. ; Madaio, Michael P. ; Madias, Nicolaos E. / Enalapril in the Management of Hypertension Associated With Renal Artery Stenosis. In: The Journal of Clinical Pharmacology. 1987 ; Vol. 27, No. 1. pp. 32-40.
@article{2db9c13ef36a4b7a8263bb8efc2eb857,
title = "Enalapril in the Management of Hypertension Associated With Renal Artery Stenosis",
abstract = "Enalapril maleate (MK‐421) is a new non‐sulfhydryl‐containing converting‐enzyme inhibitor that has been shown to be effective and well tolerated in patients with essential hypertension. Data on its effectiveness and safety in patients with renovascular hypertension are limited and have involved predominantly short‐term observations. This is particularly true with respect to the long‐term effects of enalapril on renal function. We report our experience using the combination of enalapril and hydrochlorothiazide (HCTZ) in a group of nine patients with moderate to severe hypertension associated with renal artery stenosis. The enalapril‐HCTZ combination successfully controlled blood pressure in seven patients during a six‐week period of study. Adverse effects were not noted, and detailed renal hemodynamic studies did not reveal any significant changes of renal plasma flow and glomerular filtration rate during this time interval. Five patients were continued on this regimen for a period of six to 18 months. In this group of patients, the regimen continued to be well tolerated and to provide excellent blood pressure control: glomerular filtration rate was maintained in two patients and variable grades of decrease were noted in three. The mechanism of this delayed renal dysfunction as well as its relationship to enalapril treatment remain unclear. The long‐term impact of converting‐enzyme inhibition on renal function requires further study. 1987 American College of Clinical Pharmacology",
author = "Canzonello, {Vincent J.} and Madaio, {Michael P.} and Madias, {Nicolaos E.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1177/009127008702700105",
language = "English (US)",
volume = "27",
pages = "32--40",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Enalapril in the Management of Hypertension Associated With Renal Artery Stenosis

AU - Canzonello, Vincent J.

AU - Madaio, Michael P.

AU - Madias, Nicolaos E.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Enalapril maleate (MK‐421) is a new non‐sulfhydryl‐containing converting‐enzyme inhibitor that has been shown to be effective and well tolerated in patients with essential hypertension. Data on its effectiveness and safety in patients with renovascular hypertension are limited and have involved predominantly short‐term observations. This is particularly true with respect to the long‐term effects of enalapril on renal function. We report our experience using the combination of enalapril and hydrochlorothiazide (HCTZ) in a group of nine patients with moderate to severe hypertension associated with renal artery stenosis. The enalapril‐HCTZ combination successfully controlled blood pressure in seven patients during a six‐week period of study. Adverse effects were not noted, and detailed renal hemodynamic studies did not reveal any significant changes of renal plasma flow and glomerular filtration rate during this time interval. Five patients were continued on this regimen for a period of six to 18 months. In this group of patients, the regimen continued to be well tolerated and to provide excellent blood pressure control: glomerular filtration rate was maintained in two patients and variable grades of decrease were noted in three. The mechanism of this delayed renal dysfunction as well as its relationship to enalapril treatment remain unclear. The long‐term impact of converting‐enzyme inhibition on renal function requires further study. 1987 American College of Clinical Pharmacology

AB - Enalapril maleate (MK‐421) is a new non‐sulfhydryl‐containing converting‐enzyme inhibitor that has been shown to be effective and well tolerated in patients with essential hypertension. Data on its effectiveness and safety in patients with renovascular hypertension are limited and have involved predominantly short‐term observations. This is particularly true with respect to the long‐term effects of enalapril on renal function. We report our experience using the combination of enalapril and hydrochlorothiazide (HCTZ) in a group of nine patients with moderate to severe hypertension associated with renal artery stenosis. The enalapril‐HCTZ combination successfully controlled blood pressure in seven patients during a six‐week period of study. Adverse effects were not noted, and detailed renal hemodynamic studies did not reveal any significant changes of renal plasma flow and glomerular filtration rate during this time interval. Five patients were continued on this regimen for a period of six to 18 months. In this group of patients, the regimen continued to be well tolerated and to provide excellent blood pressure control: glomerular filtration rate was maintained in two patients and variable grades of decrease were noted in three. The mechanism of this delayed renal dysfunction as well as its relationship to enalapril treatment remain unclear. The long‐term impact of converting‐enzyme inhibition on renal function requires further study. 1987 American College of Clinical Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0023555030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023555030&partnerID=8YFLogxK

U2 - 10.1177/009127008702700105

DO - 10.1177/009127008702700105

M3 - Article

C2 - 2824570

AN - SCOPUS:0023555030

VL - 27

SP - 32

EP - 40

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -